ArticleAntimicrobial agents and chemotherapy2021
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Efficacy of Inhalational Ciprofloxacin (Apulmiq) in an NHP Model of Q Fever.Antibiotics (Basel, Switzerland) · 2026Article
- Cryo-EM reveals multiple mechanisms of ribosome inhibition by doxycycline.Nature communications · 2026Article
- Inhaled Ciprofloxacin as an Alternative Treatment for Infection withAntibiotics (Basel, Switzerland) · 2026Article
- Misdiagnosed acute Q fever due to Coxiella burnetii in Guangxi China: A case report and literature review.IDCases · 2026Article
- Two Cases of Q Fever in Pregnancy, including Management of the Newborn, Australia.Emerging infectious diseases · 2026Review
- Characterization of enterotoxin, antibiotic resistance genes, and antimicrobial susceptibility profiling ofOpen veterinary journal · 2025Article
- An evaluation of antibiotic options for the treatment of biothreat pathogens.Frontiers in antibiotics · 2025Review
- Macrophage infectivity potentiator protein, a peptidyl prolyl cis-trans isomerase, essential for Coxiella burnetii growth and pathogenesis.PLoS pathogens · 2023Article
- Evaluation of Alternative Doxycycline Antibiotic Regimes in an Inhalational Murine Model of Q Fever.Antibiotics (Basel, Switzerland) · 2023Article
- The mitochondrial UPR regulator ATF5 promotes intestinal barrier function via control of the satiety response.Cell reports · 2022Article
- Antibiotic persistence of intracellular Brucella abortus.PLoS neglected tropical diseases · 2022Article
- Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells.Antimicrobial agents and chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole) against C. burnetii using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.